ASX:HYD

Hydrix (HYD) Stock Price, News & Analysis

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
N/A
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
5.53%
Price Target
N/A
HYD stock logo

About Hydrix Stock (ASX:HYD)

Hydrix Limited provides product design, engineering, and regulatory consulting services in Australia, Singapore, Europe, North America, and internationally. The company operates through three segments: Hydrix Services, Hydrix Medical, and Hydrix. Its products portfolio comprises The GUARDIAN, a cardiac monitoring device that alerts and warns patients to seek medical attention for acute coronary syndrome (ACS), including silent heart attacks; LUDO, a customizable plug-and-play platform that offers critical tools to start MCS pump development; EchoSolv, a cloud-based decision support platform, which provides physicians with tools to identify patients at-risk of structural heart disease; and Implicity, an AI-driven RM solution that delivers cardiovascular monitoring technology and data management tools, which supports health professionals in the diagnosis, rehabilitation, and surveillance of cardiovascular patients. The company also offers a range of services, including product development, and regulatory and clinical consulting. It serves industrial, utilities, defense, aerospace, and mining industries. The company was formerly known as Panorama Synergy Limited and changed its name to Hydrix Limited in November 2018. Hydrix Limited was incorporated in 1993 and is headquartered in Mulgrave, Australia

HYD Stock News Headlines

Hydrix Limited (HYD.AX)
UK companies begin world's largest 4-day working-week trial
Peak Minerals hones in on Murchison exploration opportunities
Is Hydrix (ASX:HYD) A Risky Investment?
See More Headlines
Receive HYD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Hydrix and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry
Scientific & Technical Instruments
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
70
Year Founded
N/A

Profitability

Net Income
$-2,230,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$12.66 million
Book Value
A$0.01 per share

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
1.64
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Gavin Coote
    Executive Chairman
  • Mr. Gareth Evans
    Group Head of Finance
  • Ms. Alyn Tai L.L.B.
    LLB (Hons), Corporate Counsel & Company Secretary
  • Mr. Alan Morris
    Group Marketing Director
  • Robert Brierley
    Global Director of Human Resource
  • Dr. John Bumgarner
    Chief Research Officer
  • Mr. Peter R. Lewis A.M.
    Executive Vice President of Business Development
  • Mr. Paul Kelly
    GM of Hydrix Medical & Member of Medical Advisory Board
  • Dr. Stewart James Washer B.Sc. (Age 54)
    BSc (Hons), Ph.D., Specialist Biosciences Adviser & Member of Advisory Board

This page (ASX:HYD) was last updated on 5/18/2024 by MarketBeat.com Staff

From Our Partners